FDA clears cloud-connected wearable arrhythmia monitor

A wearable device that continuously monitors a patient's ECG to detect cardiac arrhythmias and automatically relay that information to physicians has received FDA approval, St. Paul, Minn.-based VivaQuant announced.

The RX-1 device tracks patients' ECGs throughout their regular daily routines and, when an arrhythmia is detected, uses its built-in cellular connection to transfer that information to the cloud. Staff in a monitoring center then review the report and pass on any clinically significant data to the patients' respective physicians.

The device, which is the size of a smartphone, uses wavelet-based analytics and machine learning to identify atrial fibrillation, atrial flutter, premature ventricular contractions, bradycardia, tachycardia and pauses. The RX-1 is also capable of eliminating up to 95 percent of extraneous electrical noise from ECGs, which can cause false positives, missed cardiac events and other errors.

More articles about health IT:
70% of consumers say online reputation is critical when choosing a healthcare provider, survey finds
Amazon to double its tech workforce at Denver campus
Microsoft, Imprivata to launch healthcare cloud platform: 3 notes

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like